Enzo Biochem (FRA:EZB) Cash And Cash Equivalents : €55.30 Mil (As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Cash And Cash Equivalents?

Enzo Biochem's quarterly cash and cash equivalents declined from Jul. 2023 (€74.47 Mil) to Oct. 2023 (€65.54 Mil) but then stayed the same from Oct. 2023 (€65.54 Mil) to Jan. 2024 (€55.30 Mil).

Enzo Biochem's annual cash and cash equivalents increased from Jul. 2021 (€11.44 Mil) to Jul. 2022 (€21.24 Mil) and increased from Jul. 2022 (€21.24 Mil) to Jul. 2023 (€74.47 Mil).

Enzo Biochem Cash And Cash Equivalents Historical Data

The historical data trend for Enzo Biochem's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Cash And Cash Equivalents Chart

Enzo Biochem Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Cash And Cash Equivalents

Get a 7-Day Free Trial

53.65

41.64

11.44

21.24

74.47

Enzo Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash And Cash Equivalents	Get a 7-Day Free Trial															4.69	2.40	74.47	65.54	55.30

Enzo Biochem Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Enzo Biochem (FRA:EZB) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Enzo Biochem Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (FRA:EZB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (FRA:EZB) » Definitions » Cash And Cash Equivalents

Comparable Companies

NOTV VNRX BIOQ STIM PSNL PRE OCX MDXH TTOO XGN TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

ENZ:USA

Address

527 Madison Avenue, New York, NY, USA, 10022

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Enzo Biochem (FRA:EZB) Headlines

No Headlines